Abstract Library

#256 Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors

Introduction: Bone mineral density (BMD) and fractures are influenced by diet, activity, drugs and hormones. Recent studies highlight an inverse relationship between serotonin and BMD.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Den Gupta P, Grozinsky-Glasberg S, Shimon I, Drake W, Akker S,

Keywords: bone density, carcinoid, serotonin, 5-HIAA, DXA ,

#30 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

Introduction: Normal adult lungs contain scattered pulmonary neuroendocrine cells (PNEC). Reactive PNEC hyperplasia is commonly observed in persons who live at high altitude, in cigarette smokers, and in numerous lung diseases. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare entity in which PNEC hyperplasia appears without predisposing conditions. According to the 1999 WHO lung tumor classification, DIPNECH is thought to be primarily a neuroendocrine proliferative process, which can be associated with carcinoid tumors and with a clinical picture of constrictive obliterative bronchiolitis. To date, available data regarding the treatment and the prognosis of this rare condition is limited.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Grozinsky-Glasberg S

Authors: Gorshtein A, Barak D, Shimon I, Gross D, Grozinsky-Glasberg S,

Keywords: DIPNECH, neuroendocrine, hyperplasia, somatostatin analogues,

#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas

Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grozinsky-Glasberg S, Barak D, Fraenkel M, Müeller J, Shimon I,

Keywords: PRRT, malignant gastrinoma, treatment, anti-tumor effect ,